Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference36 articles.
1. International Diabetes Federation. Diabetes Atlas. 4th edition. Available at: www.diabetesatlas.org . Accessed November 1, 2010.
2. Yorkshire & Humber Public Health Observatory. APHO diabetes prevalence model. Available at: www.yhpho.org.uk/resource/view.aspx?RID=81090 . Accessed November, 2010.
3. Lankas GR, Leiting B, Roy RS, et al. Dipeptidyl peptidase IV inhibition for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidases 8 and 9. Diabetes. 2005;54:2988–2994.
4. Kirby M, Yu DM, O’Connor S, et al. Inhibitor selectivity in the clinical application of dipeptidyl peptidase-4 inhibition. Clin Sci. 2010;118:31–41.
5. Thomas L, Eckhardt M, Langkopf E, Tadayyon M, Himmelsbach F, Mark M. (R)-8-(3-Amino-piperidin-1-yl)-7-but-2-ynyl-3-methyl-1-(4-methyl-quinazolin-2-ylmethyl)-3,7-dihydro-purine-2,6-dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase-4 inhibitors. J Pharmacol Experimental Therapeut. 2008;325:175–182.
Cited by
37 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献